

# Matthew J Memoli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/666660/publications.pdf>

Version: 2024-02-01

17  
papers

1,350  
citations

687363

13  
h-index

888059

17  
g-index

24  
all docs

24  
docs citations

24  
times ranked

2326  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. <i>MBio</i> , 2016, 7, e00417-16.	4.1	283
2	Validation of the Wild-type Influenza A Human Challenge Model H1N1pdMIST: An A(H1N1)pdm09 Dose-Finding Investigational New Drug Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 693-702.	5.8	135
3	Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses. <i>Journal of Clinical Immunology</i> , 2021, 41, 906-913.	3.8	133
4	Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. <i>Science Translational Medicine</i> , 2021, 13, eabj7790.	12.4	133
5	Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling. <i>Nature Communications</i> , 2021, 12, 113.	12.8	115
6	Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	106
7	Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus. <i>MBio</i> , 2018, 9, .	4.1	81
8	A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model. <i>Clinical Infectious Diseases</i> , 2019, 69, 2082-2090.	5.8	55
9	Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model. <i>Nature Medicine</i> , 2020, 26, 1240-1246.	30.7	42
10	Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI). <i>PLoS ONE</i> , 2018, 13, e0194180.	2.5	32
11	Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model. <i>BMC Infectious Diseases</i> , 2018, 18, 353.	2.9	29
12	Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model. <i>Clinical Infectious Diseases</i> , 2021, 73, e4260-e4268.	5.8	22
13	Sex Differences in Influenza: The Challenge Study Experience. <i>Journal of Infectious Diseases</i> , 2022, 225, 715-722.	4.0	21
14	Effect of D614G Spike Variant on Immunoglobulin G, M, or A Spike Seroassay Performance. <i>Journal of Infectious Diseases</i> , 2021, 223, 802-804.	4.0	17
15	SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. <i>Emerging Infectious Diseases</i> , 2022, 28, 440-444.	4.3	15
16	An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	10
17	Deep sequencing of 2009 influenza A/H1N1 virus isolated from volunteer human challenge study participants and natural infections. <i>Virology</i> , 2019, 534, 96-107.	2.4	8